News

Medidata’s Cutting-Edge Technology Platform to Drive Operational Excellence and Patient Value for Global BiopharmaNew York, NY – Medidata, the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that UCB has selected the Medidata Clinical Cloud as its enterprise technology platform.

Greenphire and the Society for Clinical Research Sites (SCRS) released a new survey that revealed the negative impact that manual payment processes have on global clinical research.

endpoint Clinical has updated its IRT platform, PULSE, by combining it with its inventory management tool, DRIVE, to create a single solution for IRT capabilities.Read the full release here

At the end of April, European Immunization Week will take place celebrating the achievements of immunization in healthcare. However, contemporary sentiments of skepticism threaten to dampen the event.

Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017.

The Coalition for Clinical Trials Awareness will host a Capitol Hill policy roundtable featuring industry professionals on Wednesday, May 3rd. This event is part of the nationwide Clinical Trials Awareness Week taking place from May 1-5th.Read the full release here

Patient advocates, congressional staff and researchers to discuss how the federal government can increase clinical trials awareness 

San Francisco, CA – endpoint Clinical, a leading global interactive response technology (IRT) company, has announced a significant enhancement to its proprietary PULSE platform, reshaping the way IRT is applied to clinical trials.

The global skills shortage in the clinical research sector is being exacerbated in the U.K. by the uncertainty created by Brexit.

Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.

Western IRB announced an alliance with global professional services firm Huron.

As clinical trials remain costly and continue to increase, the promise of novel initiatives gives hope that trial duration and cost impact will drop. However, biopharma continues to overlook one element that affects study timelines: patient non-adherence.

Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.Read the full release here

Veeva Systems has announced the release of Veeva Vault Exchange, TransCelerate has selected this platform.

Novotech announced that it has signed a Memorandum of Understanding (MOU) with South Korean medical institution, The Asan Medical Center.

Cliantha Research is proud to announce the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON; Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. Inflamax’s world renowned expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialized pulmonary/respiratory therapeutic studies.

Initial findings from a DIA study of patient-centric initiatives in drug development reveal pharma’s desire to move toward true patient-centricity, but approaches to implementation are varied.

Certara announced the launch of a new solution for preparing, analyzing and submitting pharmacokinectic data in Clinical Data Exchange Standards Consortium (CDISC) format.Read the full release here

A certified CDISC provider and leader in pharmacometrics, Certara has developed a new solution which will enable sponsors to achieve new compliance requirements effortlessly

ePatientFinder and Rep Network have announced a partnership that aims to provide clinical trial access to patients nationally.